Abstract
Backgronnd. α-IFN is reported to be an effective treatment for a number of lymphoproliferative diseases. Little information is available at present on its effect in unaggressive immunoproliferative disorders. Study design and results. In a prospective non randomized study, 57 patients with IgG or IgA MGUS, smouldering myeloma or stage I MM treated with α-IFN (3 MU 3 times a week for at least 6 months) were compared to 129 untreated similar patients. Four patients in the IFN group showed a monoclonal component reduction >50% versus none in the control group, and 25% of patients suffered disease progression (MC increase > 50% and/or osteolytic lesions) in the IFN group as compared to 18% in the control group. Conclusions. α-IFN administration at the dose used is ineffective for the majority of patients with slowly proliferating immunoproliferative disorders; only a small subgroup of them may benefit from such a treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 35-39 |
| Number of pages | 5 |
| Journal | Haematologica |
| Volume | 80 |
| Issue number | 1 |
| Publication status | Published - 1995 |
Keywords
- indolent myeloma
- interferon
- monoclonal gammapathy
- stage I multiple myeloma
ASJC Scopus subject areas
- Hematology